Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

Wed, 10th Jul 2019 10:40

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus International, down 6.5%. Shares in the software company continued to slide after it reported a drop in revenue and maintained its annual guidance on Tuesday. Micro Focus on Tuesday also said its high-profile acquisition of Hewlett Packard's software business was still proving difficult to integrate into its existing operations, stressing it was a "complex and significant progamme of work". The stock is down 10% since the start of the week. ----------Ashtead Group, down 1.0%. Morgan Stanley cut the equipment rentals firm to Equal Weight from Overweight. ----------FTSE 250 - WINNERS----------JD Wetherspoon, up 3.2%. The pub chain said sales were higher in the year so far and its expectations for its current financial year are unchanged. Wetherspoon said its like-for-like sale were up 6.9% for the ten weeks to July 7, with total sales up 6.6% for the same period. Year-to-date, like-for-like sales were up 6.7% while total sales rose 7.4%. The company's financial year ends on July 28, on which date the company expects to have net debt of around GBP745 million. Since its financial year began, JD Wetherspoon has opened five new pubs and disposed of another nine, with no more openings planned for its current financial year. Chair Tim Martin said that "the company's expectation for our annual results is unchanged for the current financial year".----------Playtech, up 3.0%. JPMorgan started coverage on the gambling software provider with an Overweight rating. ----------FTSE 250 - LOSERS----------PageGroup, down 15%. The recruiter said it achieved gross profit growth in its first half but expects an annual operating profit at the lower end of market expectations due to "challenging" macroeconomic conditions. Page said total gross profit for the first half of 2019 was GBP433.5 million, a 9.5% increase as reported and also 9.5% at constant currency. For the second quarter alone, gross profit was GBP224.6 million, a 7.9% rise over its GBP208.2 million gross profit the year before and a 7.4% rise at constant currency. In both the second half and the second quarter, gross profit increased most sharply in the Americas, with reported growth of 21% to GBP69.1 million from GBP57.3 million in the first half and 19% to GBP36.9 million from GBP30.9 million in the second quarter. Europe, the Middle East & Africa - which accounted for 49% of the group's profit in the first half and 48% in the second quarter - also performed well with half-year reported profit growth of 9.3% to GBP213.1 million from GBP194.9 million. Despite this growth, 2019 operating profit is expected to be at the low end of market expectations due to a difficult economic environment, Page said. ----------Hays, down 6.0%. UBS cut the recruiter to Neutral from Buy, and it also suffered a read-across from PageGroup. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Redx Pharma. Shares in the cancer and fibrosis drug discovery company doubled to 14 pence after it signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals to sell its pan-RAF inhibitor programme. As part of the agreement, Redx will receive an upfront payment of USD3.5 million in cash but is eligible to receive up to USD203 million in development, regulatory and commercial milestone payments. The next milestone is the initiation of investigational new drug studies, followed by an IND submission to the US Food & Drug Administration. Redx also is eligible for incremental tiered royalties in "mid-single digit" percentage, based on any future net sales. ----------Xeros Technology, up 32%. The water saving and effluent reduction technology firm said its patent application for microfibre filters in domestic washing machines has been published. The patent application for the device, trademarked XFiltra, can now be licenced by domestic washing machine manufacturers. The application was published by the World Intellectual Property Organization. Xeros noted that the washing of clothes made from synthetic fibres is "the single biggest source of primary microplastics released into the oceans every year", with up to 700,000 microfibres released into the environment in just one domestic wash cycle.----------OTHER MAIN MARKET AND AIM - LOSERS----------Superdry, down 0.5%. The troubled fashion retailer reduced its annual payout after reporting a swing to loss in its most recently ended financial year. The company chopped its final dividend to 2.2 pence a share from 21.3p last year, taking the full-year payout to 11.5p per share, little more than a third the 31.2p paid in its financial 2018. Superdry said its revenue for the 52 weeks to April 27 was GBP871.7 million, broadly flat compared to GBP872.0 million reported for the same period a year ago, due to "a difficult retail climate". Superdry explained that its first half performance benefited from discounting and space growth, but it saw poor performance in the second half across all channels. The company posted a loss of GBP85.4 million, compared to GBP65.3 million profit reported a year earlier, as its underlying operating margin declined by 600 basis points to 5.5% from 11.5% the year before. Despite its struggles, Jefferies started coverage on Superdry with a Buy rating.----------

More News
1 Jun 2021 15:51

EXECUTIVE CHANGES: Tekmar hires former Kromek CFO; Redx chair departs

EXECUTIVE CHANGES: Tekmar hires former Kromek CFO; Redx chair departs

Read more
1 Jun 2021 15:51

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 May 2021 16:24

EXECUTIVE CHANGES: Imperial Brands CFO enters; DF Capital chair exits

EXECUTIVE CHANGES: Imperial Brands CFO enters; DF Capital chair exits

Read more
5 May 2021 16:37

IN BRIEF: Redx Pharma hires New York-based chief financial officer

IN BRIEF: Redx Pharma hires New York-based chief financial officer

Read more
28 Apr 2021 19:19

IN BRIEF: Redx Pharma starts dosing of first patient cohort of RXC004

IN BRIEF: Redx Pharma starts dosing of first patient cohort of RXC004

Read more
2 Mar 2021 21:39

TRADING UPDATES: Chariot expects gas in Morocco; Redx wants CFO in US

TRADING UPDATES: Chariot expects gas in Morocco; Redx wants CFO in US

Read more
23 Feb 2021 16:16

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
27 Jan 2021 14:06

IN BRIEF: Redx Pharma Full-Year Revenue Increases But Loss Widens

IN BRIEF: Redx Pharma Full-Year Revenue Increases But Loss Widens

Read more
20 Jan 2021 16:16

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Dec 2020 15:52

Director dealings: Redx CEO ups stake

(Sharecast News) - Redx Pharma revealed on Wednesday that chief executive Lisa Anson had acquired 39,998 ordinary shares in the AIM-listed drug discovery and development group.

Read more
23 Dec 2020 14:50

UK DIRECTOR DEALINGS SUMMARY: San Leon Energy CEO Cancels Share Buy

UK DIRECTOR DEALINGS SUMMARY: San Leon Energy CEO Cancels Share Buy

Read more
21 Dec 2020 18:10

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

Read more
2 Dec 2020 17:39

IN BRIEF: Redx Pharma Conditionally Raises GBP25.5 Million Via Placing

IN BRIEF: Redx Pharma Conditionally Raises GBP25.5 Million Via Placing

Read more
27 Oct 2020 15:16

IN BRIEF: Redx Pharma Hires New Chief Medical Officer From Achilles

IN BRIEF: Redx Pharma Hires New Chief Medical Officer From Achilles

Read more
9 Sep 2020 13:33

IN BRIEF: Redx Pharma Teams With Jazz To Develop Cancer Therapies

IN BRIEF: Redx Pharma Teams With Jazz To Develop Cancer Therapies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.